Remove 2010 Remove Competition Remove Leads
article thumbnail

Highly Cited Researchers 2021: How nations and institutions foster exceptional performance

Clarivate

These highly cited papers rank in the top 1% by citations for field and year from 2010 – 2020. We’re pleased to showcase some institutions that excel in a competitive global environment, supporting their Highly Cited Researchers in a way that encourages collaboration, facilitates career growth and accelerates highly innovative research.

article thumbnail

Call to arms as UK falls back in medicines manufacturing

pharmaphorum

Since 2010, the UK has fallen from 4th to 98th place in overall trade balance in pharmaceuticals, due to fierce global competition, according to the MMIP. Over the same period, similar countries – including Ireland, France, and Germany – have been moving to boosting manufacturing productivity, output, and exports. .”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

Observational studies should not be seen as competition to RCTs but as complementary to them, and as a sector we need to stop working in silos and develop an integrated and more comprehensive approach to evidence-based decision-making in safeguarding public health. EMA/95098/2010. Internet] European Medicines Agency. cited Dec2023].

Medicine 116
article thumbnail

Global comparator data signal “alarm bells” for UK Government, says APBI

pharmaphorum

Latest UK Life Sciences Competitive Indicators “ought to ring alarm bells across Government,” says ABPI. Richard Torbett, chief executive at the Association of the British Pharmaceutical Industry (ABPI) said Life Sciences Competitive Indicators (LSCI) data published last week “ought to ring alarm bells across Government”.

article thumbnail

Breaking through the forecasting fog – 3 trends that will impact critical medicine supply in 2023

pharmaphorum

Demand has also increased due to changes in prescribing protocols, leading to a higher underlying number of prescriptions for certain antibiotic medicines. He previously held regional leadership roles at Sandoz between 2005 and 2010. One prediction is that we will see more tentative moves in this direction. The impact is two-fold.

Medicine 105
article thumbnail

Achieving scale up success under economic uncertainty

European Pharmaceutical Review

Market uncertainty Rising operational costs, stiffening competition, ongoing patent expirations, evolving environmental and social governance requirements and increasing pressure on drug prices mean the industry will have to navigate thoughtfully to be successful amid this complicated mix of financial and strategic risks.

article thumbnail

Comparison of Humira biosimilars in the US and Europe

Pharmaceutical Technology

Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. Until 2010, no regulatory approval pathway for biosimilars existed in the US and the first biosimilar was only approved in the US in 2015. The biosimilar market in the US may progress differently this time.